首页> 外文期刊>The Canadian journal of cardiology >Medical therapy in patients undergoing percutaneous coronary intervention: results from the ROSETTA registry.
【24h】

Medical therapy in patients undergoing percutaneous coronary intervention: results from the ROSETTA registry.

机译:接受经皮冠状动脉介入治疗的患者的药物治疗:来自ROSETTA注册中心的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Previous studies have examined medication use among patients with coronary artery disease who have suffered an acute myocardial infarction (MI). However, little is known about medication use among patients with coronary artery disease who undergo percutaneous coronary intervention (PCI). OBJECTIVE: To examine the patterns of use of medical therapy among patients who undergo PCI; and to examine the determinants of medical therapy in these patients. METHODS: The Routine versus Selective Exercise Treadmill Testing after Angioplasty (ROSETTA) registry is a prospective multicentre study examining the use of functional testing after PCI. The medication use was examined among 787 patients who were enrolled in the ROSETTA registry at 13 clinical centres in five countries. RESULTS: Most patients were men (mean age 61+/-11 years, 76% male) who underwent single vessel PCI (85%) with stent implantation (58%). At admission, discharge and six months, rates of acetylsalicylic acid use were 77%, 96% and 93%, respectively (discharge versus six months, P<0.0001). Rates of use of other oral antiplatelet agents were 11%, 59% and 2% (P=0.02). For individual anti-ischemic medications, rates of use were as follows: beta-blockers 49%, 58% and 59% (P<0.0001); calcium antagonists 34%, 43% and 42% (P<0.0001); and nitrates 42%, 56% and 43% (P<0.0001). Rates of use of combination anti-ischemic medications were as follows: triple therapy 7%, 9% and 9% (P<0.0001); double therapy 34%, 47% and 38% (P<0.0001); monotherapy 36%, 36% and 41% (P<0.0001); and no anti-ischemic therapy 23%, 8% and 12% (P<0.0001). Rates of use of angiotensin-converting enzyme inhibitors were 25%, 33% and 32% (P<0.0001), and rates of use of lipid lowering agents were 41%, 52% and 61% (P<0.0001). CONCLUSIONS: Trials and guidelines statements have favourably affected the rates of use of acetylsalicylic acid and other antiplatelet agents after PCI. However, in spite of patients undergoing a successful revascularization procedure, physicians do not reducethe use of anti-ischemic medical therapy.
机译:背景:先前的研究已经检查了患有急性心肌梗塞(MI)的冠心病患者的药物使用情况。但是,对于接受经皮冠状动脉介入治疗(PCI)的冠心病患者中的药物使用知之甚少。目的:探讨接受PCI治疗的患者的药物治疗方式;并检查这些患者中药物治疗的决定因素。方法:血管成形术(ROSETTA)注册后的常规与选择性运动跑步机测试是一项前瞻性多中心研究,旨在检查PCI后功能测试的使用。在五个国家的13个临床中心的ROSETTA注册中心对787名患者进行了药物使用检查。结果:大多数患者是男性(平均年龄61 +/- 11岁,男性76%),他们接受了单血管PCI手术(85%)并植入了支架(58%)。在入院,出院和六个月时,乙酰水杨酸的使用率分别为77%,96%和93%(出院与六个月相比,P <0.0001)。其他口服抗血小板药的使用率分别为11%,59%和2%(P = 0.02)。对于个别抗缺血药物,其使用率如下:β受体阻滞剂49%,58%和59%(P <0.0001);钙拮抗剂34%,43%和42%(P <0.0001);硝酸盐分别为42%,56%和43%(P <0.0001)。联合抗缺血药物的使用率如下:三联疗法7%,9%和9%(P <0.0001);双重疗法34%,47%和38%(P <0.0001);单一疗法36%,36%和41%(P <0.0001);没有抗缺血治疗的比例分别为23%,8%和12%(P <0.0001)。血管紧张素转化酶抑制剂的使用率为25%,33%和32%(P <0.0001),降脂剂的使用率为41%,52%和61%(P <0.0001)。结论:试验和指南声明对PCI后乙酰水杨酸和其他抗血小板药物的使用率产生了有利影响。但是,尽管患者已成功进行了血运重建手术,但医生并没有减少抗缺血性药物治疗的使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号